Multistep algorithmic testing in which a sensitive nucleic acid amplification test (NAAT) is followed by a specific toxin A and toxin B enzyme immunoassay (EIA) is among the most accurate methods for Clostridium difficile infection (CDI) diagnosis. The obvious shortcoming of this approach is that multiple tests must be performed to establish a CDI diagnosis, which may delay treatment. Therefore, we sought to determine whether a preliminary diagnosis could be made on the basis of the quantitative results of the first test in algorithmic testing, which provide a measure of organism burden. To do so, we retrospectively analyzed two large collections of samples (n ϭ 2,669 and n ϭ 1,718) that were submitted to the laboratories of two Dutch hospitals for CDI testing. Both hospitals apply a two-step testing algorithm in which a NAAT is followed by a toxin A/B EIA. Of all samples, 208 and 113 samples, respectively, tested positive by NAAT. Among these NAAT-positive samples, significantly lower mean quantification cycle (C q ) values were found for patients whose stool eventually tested positive for toxin, compared with patients who tested negative for toxin (mean C q values of 24.4 versus 30.4 and 26.8 versus 32.2; P Ͻ 0.001 for both cohorts). Receiver operating characteristic curve analysis was performed to investigate the ability of C q values to predict toxin status and yielded areas under the curve of 0.826 and 0.854. Using the optimal C q cutoff values, prediction of the eventual toxin A/B EIA results was accurate for 78.9% and 80.5% of samples, respectively. In conclusion, C q values can serve as predictors of toxin status but, due to the suboptimal correlation between the two tests, additional toxin testing is still needed.
C lostridium difficile (recently reclassified as Clostridioides difficile based on phenotypic, chemotaxonomic, and phylogenetic analyses [1] ; for simplicity and consistency with previous literature, C. difficile is used in this paper) is an anaerobic, sporeproducing bacterium that is responsible for C. difficile infection (CDI), the leading cause of nosocomial infectious diarrhea (2) . Symptoms range from mild self-limiting diarrhea to potentially life-threatening fulminant colitis (3, 4) . CDI occurs when alterations in the gut microbiome, particularly antibiotic-induced disruptions, create conditions favorable for C. difficile proliferation (5) . Proliferation is followed by production of one or two enterotoxins, known as toxins A and B (toxin A/B), and in some strains a binary toxin, C. difficile transferase (CDT), whose inflammatory and necrotic effects on colonic tissue mediate the clinical symptoms of CDI (2) .
CDI diagnostic methods continue to present problematic shortcomings. Establishing a CDI diagnosis is dependent on demonstrating the presence of toxin or toxigenic organism in stool samples (6) . The two reference methods for doing so, namely, cell cytotoxicity neutralization assay (CCNA) and toxigenic culture, are lengthy laborious techniques whose clinical implementation is unrealistic. Therefore, rapid tests with the same aims have been developed. Enzyme immunoassays (EIAs) can be used to detect either toxin A/B or glutamate dehydrogenase (GDH), an abundant enzyme whose presence is indicative of C. difficile (both toxigenic and nontoxigenic strains). Similarly, nucleic acid amplification tests (NAATs) can detect the presence of toxin-producing genes. While these rapid tests are easily carried out in clinical settings, they too suffer from drawbacks. Toxin A/B EIA use was once widespread, given the etiological relationship between toxin and clinical symptoms, but recognition of the assay's low sensitivity (6) has changed this paradigm. Increasingly, NAATs have gained popularity, given their ease of use and high sensitivity. However, there is considerable debate regarding whether the presence of toxigenic organism alone warrants a diagnosis of CDI or should instead be considered C. difficile colonization (7) (8) (9) (10) . This has prompted the creation of multistep algorithms in which a first sensitive test (a NAAT or GDH EIA) is used to screen for the organism; in the event of a positive result, a highly specific second test for toxin detection (toxin A/B EIA) is used (6) .
The algorithmic approach is currently recommended by common guidelines, such as those published by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (6) . While algorithms do well to minimize false-positive and falsenegative results, their obvious shortcoming is that, in the event of a positive first test, a second test must be performed to establish a diagnosis, potentially delaying treatment and isolation of true CDI patients or leading to premature treatment of non-CDI patients. In light of this shortcoming, we sought to determine whether the quantitative results of the first test (toxin A/B or toxin B NAAT) in a two-step algorithm could predict the eventual outcome of the second test (toxin A/B EIA).
Statistical analysis.
Average C q values were compared by t test and analysis of variance (ANOVA). The ability of C q values to predict toxin presence was assessed with receiver operating characteristic (ROC) curves. Positive predictive values and negative predictive values were calculated for different C q cutoff points. Results were considered significant below the 0.05 level. Analyses of data were performed using SPSS 23.0 statistical software (IBM, Armonk, NY, USA) and Stata SE 12.1 statistical software (StataCorp, College Station, TX, USA).
RESULTS
LUMC. In total, 2,669 unformed stool samples from patients suspected of having CDI were tested with an in-house NAAT. Of those, 2,424 had negative results and 17 showed inhibition with the NAAT and were excluded from further analysis. Of the remaining 228 NAAT-positive samples, 20 were excluded from further analysis because the toxin A/B EIA was not performed (either because there was an insufficient amount of feces to perform the assay or because the assay was stopped for another reason). The remaining samples underwent toxin A/B EIA testing, yielding a final sample size of 208 ( Fig. 1, top) . C q values for patients with positive (n ϭ 78) or negative (n ϭ 130) toxin A/B EIA results and for asymptomatic individuals who were found, via culture, to be asymptomatically colonized by C. difficile upon hospital admission are shown in Fig. 2 , top. Comparable mean C q values were observed for symptomatic patients with negative toxin results (mean C q , 30.4 [95% confidence interval [CI], 29.5 to 31.3]) and asymptomatic carriers (mean C q , 29.2 [95% CI, 27.3 to 31.2]), while symptomatic patients with positive toxin results had significantly lower mean C q values, according to ANOVA (mean C q , 24.4 [95% CI, 23.5 to 25.3]; P Ͻ 0.001). Seventeen outliers that were positive by toxin A/B EIA and had high C q values were retested with a TcdB NAAT; the mean C q value for those samples did not decrease after retesting. Samples were evaluated for PCR inhibition or irregular amplification curves, but neither was found to be a cause of these anomalies. Clinical data showed that only 1 of these samples was submitted for CDI testing during metronidazole treatment, 14 samples were submitted while no CDI antibiotics were being used, and antibiotic use was not clear for 2 samples. All except 1 of these 17 samples exhibited positive culture results, yielding 11 different ribotypes. The only culture-negative sample was from a patient with clinical suspicion of a CDI recurrence 4 months after a previous episode. After the positive CDI test result, the patient received oral metronidazole treatment.
Based on the significantly lower C q values observed for toxin-positive samples, a ROC curve was generated to calculate the ability of C q values to predict toxin A/B EIA outcomes ( Fig. 3, top) . The area under the curve (AUC) was found to be 0.826 (P Ͻ 0.001), with an ideal cutoff value of 25.3 cycles (the value best able to discriminate between outcomes); 78.9% of samples would be correctly classified as toxin A/B EIA positive or negative using this C q cutoff value. Measures of accuracy for the ideal cutoff value and others are shown in Table 1 .
Because LUMC data included PCR ribotypes, we investigated whether ribotype had an effect on our findings. Ribotype distributions were comparable for toxin A/B EIA-positive and -negative patients, by the chi-squared test (P ϭ 0.26), and we did not find any differences in the mean C q values for different ribotype categories (P ϭ 0.55 for toxin-negative samples and P ϭ 0.11 for toxin-positive samples) ( Table 2) .
Amphia Hospital. A total of 1,718 unformed stool samples from patients suspected of having CDI were tested with an in-house NAAT (different from the LUMC NAAT). Of those, 1,589 had negative results and 8 showed inhibition and were excluded from further analysis. Seven of the 121 NAAT-positive samples were not tested with the toxin A/B EIA (2 were repeat samples from the same patient on the same day, 1 sample was from a gut biopsy, and 4 other samples were not tested otherwise). The remaining 114 samples underwent toxin A/B EIA testing. One sample had an invalid result from the second test (no detectable color in the reaction port) and was also excluded from further analysis, yielding a final sample size of 113 (Fig. 1, bottom) . C q values for toxin-positive (n ϭ 31) and toxin-negative (n ϭ 82) samples are shown in Fig. 2 , bottom. Significantly lower mean C q values were found for toxin-positive patients than for toxin-negative patients (mean C q values of 26.8 [95% CI, 25.8 to 27.9] versus 32.2 [95% CI, 31.3 to 33.0]; P Ͻ 0.001). Evaluation of the 1 outlier that was positive by toxin A/B EIA and had a high C q value revealed a normal shape for the amplification curve but no diarrhea at the time of the results (without treatment).
As performed for the other cohort, a ROC curve was generated to determine the ability of C q values to predict toxin A/B EIA outcomes (Fig. 3, bottom) . The AUC was 0.854 (P Ͻ 0.001), with an ideal cutoff value of 27.0; 80.5% of samples would be correctly classified. Measures of accuracy for the ideal cutoff value and others are shown in Table 1 .
DISCUSSION
This study sought to determine whether quantitation of NAAT results could predict the presence or absence of toxin in subsequent testing. Significantly lower C q values were found in stool samples that tested positive for toxin in two large cohorts from different hospitals. Concomitant ROC curves for both cohorts showed that, using the optimal C q cutoff value, the toxin result could be predicted for at least 78% of the samples. With the recent emergence of NAATs as standalone tests or as the first step in an algorithm, there has been increasing interest in the use or nonuse of quantitation of NAAT results. There is a growing body of work showing an association between C q values and toxin presence; toxin-positive samples are associated with lower C q values or greater bacterial loads (15) (16) (17) (18) (19) (20) (21) (22) . Toxin presence is generally thought to be associated with CDI severity and outcomes (7, 8) . Some studies indeed found C q values to be predictors of clinical severity or outcomes, probably mediated through the presence or absence of toxins (22-24), although this was not confirmed in all studies (25, 26) . A very recent paper was the first to describe the performance characteristics of NAAT C q cutoff values for discriminating toxin-positive and toxin-negative stool samples (27) . Our study adds to the literature by confirming that C q values can indeed be used to predict toxin status. In our two cohorts, the optimal C q cutoff values detected toxin-positive samples with positive and negative predictive values of 71.8% and 83.1% and 69.6% and 83.3%, respectively. Our study also indicates that local assessment of NAAT performance is warranted to determine cutoff values that can be adopted for clinical use, as C q values are semiquantitative and depend on many factors involving the sample material, materials used, and assay conditions. Clinical implementation of these findings may be beneficial. Algorithmic testing requires more time to establish a CDI diagnosis than standalone tests, which has been shown to negatively affect patient care (28) . One way of addressing this problem would be to use C q values to establish a preliminary diagnosis; this can be done by using the optimal C q cutoff values to consider samples either likely toxin positive or likely toxin negative. Using this approach, as many samples as possible will be classified correctly. It might be argued, however, that toxin-positive samples should not be missed, as delayed treatment or delayed isolation measures may negatively affect patient care and C. difficile transmission. In that case, a C q cutoff value with a high negative predictive value should be chosen, to classify samples with C q values above the cutoff value as probably toxin negative. As an example, C q cutoff values of 29.0 and 32.0 for the LUMC and Amphia Hospital cohorts, respectively, would correctly classify 91.3% and 97.9% of (5) samples with C q values above the cutoff values as negative. A preliminary diagnosis based on one of these two approaches might be used, for instance, when a clinician considers CDI treatment for a patient before the results of toxin testing are available. We do recognize, however, that the correlation between C q values and toxin positivity and the positive and negative predictive values for the diverse cutoff values are far from perfect. Therefore, we think that C q values may be helpful in questionable cases but NAAT quantitation should not be seen as a surrogate for free toxin testing or clinical judgment. It would be interesting to investigate whether the incorporation of C q values into an algorithm improves patient outcomes, compared to testing in which diagnoses, and consequent treatment, are dependent exclusively on demonstrating the presence of toxin.
Our study had some limitations. First, we used EIAs to detect toxin, tests that are known to suffer from low sensitivities. Automated toxin A/B EIAs such as the Vidas C. difficile Toxin A&B test used by the LUMC have reported sensitivities ranging from 53 to 98%, compared to CCNA; membrane-type toxin A/B EIAs such as the ImmunoCard Toxins A&B test have sensitivities ranging from 85 to 96%, compared to CCNA (6) . It is possible that some of the outliers we observed, with low C q values but no toxin present, were actually false-negative results from the toxin A/B EIA. CCNA, the gold standard of toxin detection, ideally should have been used but, because these analyses were conducted retrospectively, using clinical data with toxin testing performed with toxin A/B EIAs, this was not possible. In the study by Senchyna and colleagues, a membranetype EIA that detected both GDH and toxin A/B, CCNA, and a well-type toxin A/B EIA were combined to detect toxin-positive samples (27) . Using these combined tests as the reference standard, the optimal threshold cycle (C T ) cutoff value detected toxinpositive samples with a positive predictive value of 81.7%, somewhat greater than those found for our cohorts, which may be explained by the more sensitive reference standard those authors used. A second limitation of our study is that we analyzed all samples that were tested for CDI and did not exclude samples from the same patient, samples from children, samples obtained during the same diarrheal episode, or samples submitted during or after treatment. The heterogeneity of the cohorts may have obscured some associations, such as higher C q values for certain ribotypes, as reported previously for ribotype 014 (21) , or an aberrant association between C q values and toxin positivity in children. However, the inclusion of all submitted samples yielded cohorts that are representative of the actual situations. Information on repeat samples and CDI treatment is often lacking, and the eventual ribotype (if CDI is confirmed) is not available when the samples arrive at the laboratory. Therefore, we think that this study demonstrated the usefulness of NAAT quantitation in two unbiased cohorts that are highly representative of samples that are submitted for CDI testing, both in a universal hospital and in a general hospital.
Besides the representative cohorts that were used, there were some other strengths in our study. First, samples from the LUMC cohort underwent culture and PCR ribotyping and we were thus able to evaluate any differences in C q levels among different ribotype categories. Culture and ribotyping results were also used to evaluate the outliers. Because 16/17 outlier samples had positive culture results and the 1 remaining sample had a clear clinical suspicion of CDI, false-positive toxin A/B EIA results were considered less likely. Laboratory and clinical evaluations, including retesting with a TcdB NAAT, were performed, but no clear explanation for the outliers with high C q values but positive toxin A/B EIA results was found. Another strength of our study is the unique comparison with a group of asymptomatic carriers, which clearly demonstrated that C q levels among asymptomatic carriers and symptomatic patients testing negative for toxins were comparable, suggesting that the latter group indeed represented CDI carriers with diarrhea not due to CDI.
In conclusion, we found C q values to be predictors of toxin status in two large representative cohorts, although the suboptimal accuracy underscores the need for additional toxin A/B EIA testing. Additional studies are needed to determine whether the inclusion of C q values in algorithmic testing may aid clinicians in reaching faster but still accurate preliminary CDI diagnoses while awaiting the results of free toxin testing.
